{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.', 'STUDY DESIGN', '4.1.', 'Overall Design', 'This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter', 'study to evaluate the safety and efficacy of ravulizumab for the treatment in patients with gMG.', 'Approximately 160 eligible patients will be stratified by region (North America, Europe,', 'Asia-Pacific, and Japan) and randomized 1:1 to 1 of 2 treatment groups: (1) ravulizumab', 'infusion or (2) placebo infusion. There will be 3 periods in this study: Screening Period,', 'Randomized-Controlled Period, and an Open-Label Extension (OLE) Period.', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg. Starting Week 28, all', 'patients will begin open-label ravulizumab maintenance doses q8w. For patients in the', 'ravulizumab group, a blinded ravulizumab dose of 900 mg was chosen to ensure maintenance of', 'complete C5 inhibition until the next scheduled maintenance dose at Week 28 (Day 197).', 'Eight weeks after the final dose of study drug is administered, all enrolled patients will return for', 'an End of Study (EOS) Visit (Visit 25) at Week 132 during which final study assessments will', 'be conducted. If a patient withdraws from the study, or completes the study early (prior to', 'Visit 24; Week 124), the patient will be encouraged to return for an Early Termination (ET)/EOS', 'Visit, 8 weeks after the day the last dose of study drug was administered, during which final', 'planned safety assessments will be conducted (see Section 4.5 for further details regarding end of', 'study and study completion). Attempts should be made to follow all patients for safety for', '8 weeks from the day the last dose of study drug is administered.', 'Patients who are being treated with an immunosuppressive therapy (IST) at the time of the', 'Screening Visit may continue taking their baseline ISTs throughout the Randomized-Controlled', 'and OLE Periods. However, the dosage of IST must not be changed and no new ISTs may be', 'added or discontinued during the Randomized-Controlled Period of the study, unless deemed by', 'the Investigator to be medically necessary.', 'Throughout the study, rescue therapy (eg, high-dose corticosteroid, plasmapheresis (PP)/plasma', 'exchange (PE), or intravenous immunoglobulin [IVIg]) will be allowed if a patient experiences', 'Clinical Deterioration as defined in this protocol (Section 4.2.1). The rescue therapy used for a', 'particular patient will be at the discretion of the Investigator.', 'The primary endpoint for this study will be measured at Week 26 (Day 183), irrespective of', 'rescue therapy.', 'Including the 8-week safety follow-up, which begins after the last dose of study drug is', 'administered, the overall study duration for an individual patient is estimated to take up to', '132 weeks (from enrollment through the end of the Safety Follow-up). The period of active', 'patient-participation is estimated to take up to 132 weeks (from enrollment through the EOS', 'Visit). Schedules of Activities (SOA) for the Randomized-Controlled Period and the OLE Period', 'are provided in Table 1 and Table 2, respectively.', 'Page 31 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.1.1.', 'Screening Period (2 - 4 Weeks Prior to Day 1)', 'At the screening visit, after obtaining informed consent, the patient will be screened for study', 'eligibility through medical history review, demographic data, and laboratory assessments. The', 'medical history review will include MG diagnosis date; initial MG clinical presentation (ocular', 'MG [oMG] or gMG); time to gMG, if initial clinical presentation was oMG; maximum MGFA', 'classification since diagnosis; ventilatory support since diagnosis; dates of MG exacerbation or', 'crisis since diagnosis and prior to Day 1; and any MG-related hospitalizations in 2 years prior to', 'screening. MG-specific medication or therapy (eg, thymectomy, ISTs including corticosteroids,', 'IVIg, and PE/PP) within 2 years prior to screening will be recorded.', 'If all inclusion criteria and none of the exclusion criteria are met, patients will be vaccinated', 'against N meningitidis, if not already vaccinated within the 3 years prior to their enrollment in', 'the study. Patients who initiate study drug treatment less than 2 weeks after receiving a', 'meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until', '2 weeks after vaccination.', 'If a patient experiences a Clinical Deterioration or MG Crisis during the Screening Period, the', 'Sponsor must be notified.', '4.1.2.', 'Randomization', 'At the time of randomization, all patients will be reassessed for eligibility based on the study', 'inclusion and exclusion criteria. All patients who are vaccinated, continue to meet all of the', 'inclusion criteria and none of the exclusion criteria at Randomization [Day 1]), and have been', 'cleared for randomization by the Investigator, will be randomized 1:1 to the ravulizumab group', 'or the placebo group. Patients will be centrally randomized using interactive response technology', '(IRT). The randomization will be stratified by region (North America, Europe, Asia-Pacific, and', 'Japan).', '4.1.3.', 'Randomized Controlled Period (26 Weeks)', 'Throughout the study, rescue therapy (eg, high-dose corticosteroid, PE/PP, or IVIg) will be', \"allowed when a patient's health would be in jeopardy if rescue therapy was not administered (eg,\", 'emergent situations), or if a patient experiences Clinical Deterioration as defined in this protocol.', 'The rescue therapy used for a particular patient will be at the discretion of the Investigator.', 'Patients must be informed of potential signs and symptoms of Clinical Deterioration or MG', 'Crisis and instructed to contact the Investigator to be evaluated within 48 hours of notification of', 'the Investigator of the symptom onset. At the evaluation visit, the Investigator or the', \"Investigator's designee will perform the assessments as specified by this protocol. The\", 'Investigator or designee will determine whether or not the patient meets the definition of Clinical', 'Deterioration as defined by this protocol in Section 4.2.1 and treat the patient accordingly.', 'The primary endpoint for this study will be measured at Week 26 (Day 183), irrespective of', 'rescue therapy.', 'See the SOA for further details regarding visit procedures throughout the study (Section 1.3).', 'Page 32 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}